Experimental cancer drug tested in early trial, but study stopped early
NCT ID NCT06466187
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This early-stage trial tested an experimental drug called PF-08052666 in 19 people with advanced solid tumors like lung, ovarian, and pancreatic cancers that had not responded to standard treatments. The drug is designed to target and kill cancer cells. The study aimed to find a safe dose and check for side effects, but it was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PF-08052666 (also called SGN-MesoC2), an antibody-drug conjugate given into the vein
- What this could lead to
- If it works, this could point toward a new treatment option for certain advanced solid tumors that have not responded to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial that was terminated early, so results are limited. The drug may not prove effective or safe in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, 27157, United States
-
McGill University Health Centre
Montreal, Quebec, H4A 3J1, Canada
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Mountain Region, LLC
West Valley City, Utah, 84119, United States
-
START San Antonio, LLC
San Antonio, Texas, 78229, United States
-
Sarah Cannon Research Institute - Pharmacy
Nashville, Tennessee, 37203, United States
-
The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
The University of Alabama at Birmingham
Birmingham, Alabama, 35249, United States
-
The University of Kansas Cancer Center - Indian Creek Campus
Overland Park, Kansas, 66211, United States
-
The University of Kansas Cancer Center - Westwood
Westwood, Kansas, 66205, United States
-
The University of Kansas Cancer Center, Investigational Drug Services
Westwood, Kansas, 66205, United States
-
The University of Kansas Clinical Research Center
Fairway, Kansas, 66205, United States
-
The University of Kansas Hospital
Kansas City, Kansas, 66160, United States
-
The University of Kansas Hospital Cambridge North Tower A
Kansas City, Kansas, 66160, United States
-
The University of Kansas Medical Center Medical Office Building
Kansas City, Kansas, 66160, United States
-
University Health Network
Toronto, Ontario, M5G 2C4, Canada
-
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35249, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Can a simple blood test spot ovarian cancer before it starts?
- Your gut bacteria might reveal hidden cancer risk